Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study

Abstract

An 8-month multicentre prospective randomized study comparing dopamine receptor agonists pramipexole and pergolide as add-L-dopa therapy on depression in non-demented patients suffering from both mild and moderate depression and PD.